ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 065,26
-1,53%
DAX
18 691,32
0,05%
Brent Oil
81,345
-0,23%
Bitcoin
67 418,05
-2,43%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Actualités

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CTMX
DateHeureSourceTitreSymboleSociété
22/05/202422h05GlobeNewswire Inc.CytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
17/05/202423h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
17/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
16/05/202422h15GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
13/05/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h10GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h10GlobeNewswire Inc.CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)NASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
07/05/202422h15GlobeNewswire Inc.CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:CTMXCytomX Therapeutics Inc
01/05/202414h00GlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
08/04/202414h00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
03/04/202414h00GlobeNewswire Inc.CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
21/03/202413h00GlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h10GlobeNewswire Inc.CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTMXCytomX Therapeutics Inc
11/03/202411h39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:CTMXCytomX Therapeutics Inc
04/03/202414h00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024NASDAQ:CTMXCytomX Therapeutics Inc
27/02/202414h00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
24/01/202414h00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
12/01/202414h00GlobeNewswire Inc.CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.CytomX Therapeutics Outlines 2024 Company Priorities and MilestonesNASDAQ:CTMXCytomX Therapeutics Inc
21/12/202314h00GlobeNewswire Inc.CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
07/11/202322h15GlobeNewswire Inc.CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
01/11/202313h00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
31/10/202313h00GlobeNewswire Inc.CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:CTMXCytomX Therapeutics Inc
30/10/202313h00GlobeNewswire Inc.CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
18/10/202322h30GlobeNewswire Inc.CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
05/09/202322h05GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

Dernières Valeurs Consultées

NASDAQ
BLUDE
Immucor
BIT
P1YPP7
NLBNPIT1YPP7 20240522 3
NASDAQ
AAXVWXX
Royal Bank of Canada Poi...
DBI
IIVK
Global InflationLinked B...
USOTC
STQN
Strategic Aquisitions (PK)
COIN
KBCUST
KaratBank Coin
EU
MEDCL
Medincell
NASDAQ
SJVIX
Steward Large Cap Value ...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés